|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 HKD | +0.50% |
|
+9.35% | -19.15% |
| Apr. 22 | 3Sbio Inc. Announces Management Changes | CI |
| Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
3SBio Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 6,859.43 million compared to CNY 6,382.01 million a year ago. Net income was CNY 1,914.89 million compared to CNY 1,651.25 million a year ago.
Basic earnings per share from continuing operations was CNY 0.78 compared to CNY 0.65 a year ago. Diluted earnings per share from continuing operations was CNY 0.74 compared to CNY 0.62 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.15% | 1.85B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
3SBIO INC. 
